Corona Remedies Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹1008 - ₹1062
- Lot size
- 14 shares
- Issue amount
- ₹655.37 cr
- Total subscription
- 144.49×
- Opens
- 8 Dec 2025
- Closes
- 10 Dec 2025
- Allotment
- 11 Dec 2025
- Listing
- 15 Dec 2025
Offer at a glance
Issue overview
- Issue size
- 61,71,102 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹14,112
- Fresh issue
- ₹0 cr
- Offer for sale
- ₹655.37 cr
- Registrar
- Bigshare Services Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹1,21,068
- Issue type
- Bookbuilding IPO
- Shares before issue
- 6,11,60,088
- Shares after issue
- 6,11,60,088
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 14 | ₹14,868 |
| sHNI | 14 | 196 | ₹2,08,152 |
| bHNI | 68 | 952 | ₹10,11,024 |
Share reservation
Subscription & GMP
Subscription by category
Reported 10 Dec 2025
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 1,52,827 | 37,92,248 |
| EMPLOYEES | 0 | 35,988 |
| HNIs(10L +) | 3,119 | 1,55,224 |
| HNIs (2-10L) | 1,559 | 2,49,992 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 129.75 | 38,119.37 |
| FIs | 0 | 0.81 |
| Others | 0 | 11.64 |
| RETAIL | 227.22 | 6,881.98 |
| HNIs 2+ | 32.46 | 5,427.21 |
| HNIs 10+ | 64.92 | 16,014.25 |
| EMPLOYEES | 6.16 | 95.89 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Jun-25 | Mar-25 | Mar-24 |
|---|---|---|---|
| EPS | 7.55 | 24.43 | 14.8 |
| ROE | 7.61 | 27.5 | 20.36 |
| ROCE | 11.28 | 41.32 | 31.19 |
| RONW | 20.5 | 24.65 | 18.84 |
| PRE IPO(PE) | 0 | 43.47 | 0 |
| POST IPO(PE) | 35.15 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Corona Remidies Limited | 0 | 0 | 0 | 99.14 | 24.65 | 24.43 |
| Abbott India Ltd | 45.17 | 0 | 0 | 1,992.14 | 33.41 | 665.62 |
| Alkem Laboratories Ltd | 31.39 | 0 | 0 | 1,002.37 | 18.07 | 181.11 |
| Eris Lifesciences Ltd | 25.85 | 0 | 0 | 209.73 | 12.21 | 25.85 |
| Glaxosmithkline Pharmaceuticals Ltd | 46.87 | 0 | 0 | 115.19 | 47.54 | 54.76 |
| J.b.chemicals & Pharmaceuticals Ltd | 42.45 | 0 | 0 | 220.88 | 19.21 | 42.45 |
| Mankind Pharma Limited | 45.77 | 0 | 0 | 352.51 | 13.89 | 49.28 |
| Pfizer Ltd | 29.63 | 0 | 0 | 921.88 | 18.20 | 167.79 |
| Sanofi India Ltd | 24.47 | 0 | 0 | 373.68 | 48.05 | 179.46 |
| Torrent Pharmaceuticals Ltd | 65.91 | 0 | 0 | 224.28 | 25.18 | 56.47 |
Company information
Company profile
Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas including women’s healthcare, cardiology, pain management, urology, and multispecialty segments. As of December 2024, its portfolio includes 67 brands covering women’s health, cardio-diabetic care, pain relief, urology, and multispecialty products such as vitamins, minerals, nutrition, gastrointestinal, and respiratory medications. The company has established a strong pan-India presence with 2,598 medical representatives across 22 states, ensuring deep engagement with healthcare professionals and hospitals. It operates two manufacturing facilities in Gujarat, supporting its production and quality-focused growth strategy in the Indian Pharmaceutical Market.
Strengths
- Leading Market Growth Position: The company is the second fastest-growing among the top 30 pharmaceutical players (MAT 2022–2025), well-positioned to benefit from India’s expanding pharmaceutical demand.
- Diversified & Scalable Product Range: Successfully developing multiple “engine brands” across key therapy areas—women’s health, cardio-diabetic, pain, and urology—supports sustainable long-term growth.
- Extensive Pan-India Sales Network: A broad national sales and marketing network targeting specialist doctors and mid-income patients drives prescription growth above the overall market rate.
Risk factors
- High Reliance on Key Therapy Areas: More than 60% of revenue is generated from women’s health, cardio-diabetic, and pain management segments; underperformance or intensified competition in these areas may hinder growth.
- Concentration in Major Engine Brands: 27 primary “engine brands” account for over 70% of domestic sales; any decline in top brands like B-29 or Myoril could significantly impact performance.
- Dependence on Indian Market: Over 96% of revenue comes from India; weak domestic demand or delays in international expansion could adversely affect financial stability.
Promoters
Dr. Kirtikumar Laxmidas Mehta
Niravkumar Kirtikumar Mehta
Ankur Kirtikumar Mehta
Registrar & documents
Lead manager
IIFL Capital Services Limited, Jm Financial Limited, Kotak Mahindra Capital Company
Registrar & contacts
Bigshare Services Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
CORONA House, C – Mondeal Business Park Near Gurudwara S. G. Highway Thaltej Ahmedabad, Gujarat, 380059
+91 79 4023 3000
[email protected]Company website ↗Understanding CORONA IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.